Mastering Immunity Europe 2018

Thursday 22 and Friday 23 March 2018

Wolfson College, Oxford, UK

Sign up today

Filmed Presentations from all our meetings are available online

Join our Mastering Immunogenicity LinkedIn Group

Understand and manage immune responses in drug and vaccine development

As targeted immune therapies grow in complexity, understanding and controlling immune regulation has never been more important in the design of therapeutics.

Join experts in both academic and commercial immunology at Mastering Immunity Europe 2018 for a focussed conference to learn the latest developments in this fast-developing field covering multiple aspects of in the development of modern therapeutics. This focussed meeting is a forum for key people involved in wanting to characterize immune modulation following delivery of biologics and other therapies to come together to share knowledge, perspectives and discuss solutions to the complex challenges of immunity in this context. We will focus on manipulation and characterization of both desired (in immuno-oncology and vaccines) as well as unwanted immune responses (i.e. immunogenicity to biotherapeutics or viral vectors).

This meeting, of which the Mastering Immunogenicity series is part of, is now in its seventh consecutive year having also been held in Cambridge and Boston, USA.  Free access to all recorded talks can be found here. This event in Oxford offers an unparalleled opportunity to meet and share information with like-minded scientists from other organizations, and to help shape the future of your R&D programs.

Click here for Full Programme details including Abstracts and Speaker information.


Day 1 - Thursday 22 March



Arrival and registration



Welcome and conference overview


Dr. Georg Lauer, Associate Professor of Medicine, Harvard Medical School

"Analysis of low frequency virus-specific CD4 and CD8 T cells in chronic human viral infection"


Dr. Lotta Jansson, Research Director, Apitope

"Apitopes to induce immune tolerance - mechanism and action"


Dr. Aileen Rowan, Research Associate, Imperial College

"Turnover and transformation of T cell clones in retroviral infection and leukaemia"



Coffee and Networking


Prof. Beatriz Carreno, Associate Professor of Medicine, University of Pennsylvania

"Personalized Cancer Vaccines"


Prof. Len Seymour, Professor of Gene Therapy, University of Oxford

"Oncolytic viruses for targeted cancer immunotherapy"


Prof. Paul Brenchley, University of Manchester

"Identifying T and B cell autoantigen epitopes in membranous nephropathy"





Dr. Margot El-Khouri, ProImmune

"Epitope identification and clinical immune monitoring in immune oncology programs"


Dr. Stephen Man, Reader, Cardiff University School of Medicine

"CD8+ T cell recognition of unusual and unnatural peptide epitopes"


Dr. Yongliang Zhang, Immunology Programme, Life Science Institute, National University of Singapore

"DUSP10 in inflammation and cancer"



Coffee and networking


Dr. Aline Bracher, Medigene

"A semi-automated method for the isolation and initial characterization of neoantigen-specific T cell receptors"


Dr. Richard Sainson, Kymab

"KY1044, a novel anti-ICOS antibody, elicits long term in vivo anti-tumour efficacy as monotherapy and in combination with immune checkpoint inhibitors"



Drinks reception


Day 2 - Friday 23 March


Prof. Fiona Powrie, Professor of Musculoskeletal Sciences and Director of the Kennedy Institute, University of Oxford

"Host microbe interactions in the intestine: New therapeutic strategies for the treatment of immune-mediated diseases"

Photo credit: Thomas S.G. Farnetti/Wellcome


Dr. Guy Hermans, CSO, Isogenica

"Using synthetic antibody libraries to overcome poor immunogenicity"


Dr. Katie Ewer, Associate Professor & Senior Immunologist, Jenner Institute, University of Oxford

"Measuring vaccine-induced immunogenicity in diverse populations and locations"



Coffee and Networking


Dr. Ilaria Esposito, University of Oxford

"Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV"


Dr. Isabelle Turbica, Assistant Professor in Biotechnology, Université Paris-Sud

"Impact of protein aggregates from biopharmaceuticals on dendritic cells"


Dr. Till Andlauer, Max Planck Institute of Psychiatry, Munich

"Genetic factors influencing the development of binding and neutralizing antibodies against interferon beta treatment in multiple sclerosis patients"





Dr. Jeremy Fry, ProImmune

"An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design"


Dr. Joleen White, EMD Serono

"Low Immunogenicity of Avelumab, An Immune Checkpoint Inhibitor Demonstrating Antitumor Activity"


Dr. Eleni Chantzoura, Agenus

"Targeting Phosphopeptide neoantigens through TCR-targeted cell therapy and peptide vaccines"



Closing comments and End of meeting

How will I benefit?



  • Learn the key issues facing drug developers

  • Be informed of the latest strategies for pre-clinical and clinical immune modulation

  • Quality by Design in drug development

  • Be informed of the latest technologies to keep ahead of the competition

  • Case studies

  • Exchange new ideas

  • Meet potential collaborators

  • Discuss current and developing challenges

  • Meet like-minded scientists from other organizations, and to help shape the future of your own R&D programs.

Feedback from previous conferences:

“Mastering Immunogenicity captured the breadth and depth of immunogenicity issues faced by industry today” (Tim Hickling, Pfizer)

“I also had a great time during the meeting. It was truly excellent in content and organization.” (Julio Delgado, University of Utah)

“It was a terrific event, with excellent speakers and great networking/brainstorming opportunities at the breaks and with the roundtable” (Valerie Quarmby, Genentech)

"Great first experience. I enjoyed the breadth of topics" (Laurent Malherbe, Eli Lilly)

 “Great speakers with diverse topics. I enjoyed the deep science and also the opinions from experts in the field” (Xiaoying Chen, Pfizer)

 "Covered a diverse array of subjects. I enjoyed the networking opportunities” (Shinu John, Moderna Therapeutics)

"Excellent event" (George Gunn, Janssen R&D)

"Really liked the interactive environment. In-depth discussions with very relevant colleagues"

 "I really enjoyed the very good quality, sparkling diversity, but still keeping focus"

"Very nice and comprehensive topics in this symposium. I have learnt a lot from it." (Pu Shi, Takeda)

"This is a fantastic conference that is a good mix of vaccine and biotherapeutic folks. Facilitates learning and collaboration." (Priya Sriraman, Celgene)

Conference Venue

The City of Oxford

Picture: Nasir Hamid

A fitting venue for our conference, Oxford is a world leading center in science research and education.

Situated approximately 50 miles north-west of London, modern Oxford owes much to the University, which was founded in 1096 and is the oldest university in the English speaking world. Visitors to the city can tour splendid British architecture, including such icons as the mid-18th century Radcliffe Camera, the Bodleian Library and the Bridge of Sighs.

For further information about Oxford and the surrounding area browse, “Experience Oxfordshire”, the official tourism website for Oxfordshire.


Wolfson College

Wolfson College, part of the University of Oxford, is situated within 13 acres of stunning riverside gardens. It offers a tranquil rural retreat just a short walk from Oxford city centre. Wolfson is an all-graduate college with students from 75 nations. It was founded in 1965 by Sir Isaiah Berlin, the influential political philosopher.

The conference itself will take place in Wolfson’s award-winning Leonard Wolfson Auditorium.  This building is very striking architecturally, with a remarkably shaped ceiling giving excellent acoustics, and chestnut-lined interior creating a sense of elegance and light.


Although no accommodation is available at the college, we would recommend the following establishments just a short distance away:

The Best Western Linton Lodge Hotel: www.bw-lintonlodgehotel.co.uk (2 minute walk)
Parklands Bed & Breakfast:
www.parklandsoxford.co.uk (5 minute walk)
Cotswold Lodge Hotel:
www.cotswoldlodgehotel.co.uk (10 minute walk)

Oxford is 56 miles (90km) north-west of London, with excellent bus and rail services.

By Air
There are 3 major international airports (London Heathrow, LHR; London Gatwick, LGW; Birmingham International, BHX) within 2 hours travel time. The simplest and best option if you are flying to any of these airports is to take the regular bus service direct to Oxford City. See
http://airline.oxfordbus.co.uk/timetables/  for details.
Airport Taxi Transfers: Pryors (+44 1235 812346).

By Road
The city is well served by public transport but the historic nature of the city center means parking spaces are in very short supply. There is no parking available at the conference venue. We would recommend parking at the Water Eaton Park and Ride or Peartree Park and Ride. Both are just a 15-20 minute bus ride to the conference.

By Rail
The closest rail stations are Oxford (serving direct trains from London Paddington) and Oxford Parkway (serving direct trains from London Marylebone). Both stations are a 15-20 minute direct bus ride / 10 minute taxi ride from the venue. See
www.nationalrail.co.uk for more details.

For all Conference Enquiries please contact:


Telephone (toll free): USA & Canada +1 888 505 7765
All other countries +44 (0) 870 042 7279